.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Daiichi Sankyo
Cantor Fitzgerald
Fish and Richardson
Merck
Covington
US Army
Julphar
Accenture

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,293,794

« Back to Dashboard

Which drugs does patent 8,293,794 protect, and when does it expire?


Patent 8,293,794 protects NAMZARIC and is included in one NDA. There has been one Paragraph IV challenge on Namzaric.

This patent has fifty-seven patent family members in eighteen countries.

Summary for Patent: 8,293,794

Title:Methods and compositions for the treatment of CNS-related conditions
Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:12/753,769
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo8,293,794► SubscribeY
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-001Dec 23, 2014ABRXYesNo8,293,794► SubscribeY
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-004Jul 18, 2016RXYesNo8,293,794► SubscribeY
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-002Dec 23, 2014ABRXYesYes8,293,794► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,293,794

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,233Method for administering an NMDA receptor antagonist to a subject► Subscribe
8,058,291Methods and compositions for the treatment of CNS-related conditions► Subscribe
8,362,085Method for administering an NMDA receptor antagonist to a subject► Subscribe
8,173,708Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
2,012,045,508► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,293,794

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2007012374► Subscribe
China101247795► Subscribe
China101686945► Subscribe
Germany05852057► Subscribe
Germany602006016934► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
McKinsey
Fish and Richardson
Farmers Insurance
Healthtrust
McKesson
Queensland Health
AstraZeneca
Chinese Patent Office
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot